Objective: The purpose of this study was to determine the rate of induction-remission among the patients of Acute Myeloid Leukemia in medical oncology department of the Jinnah Postgraduate Medical Centre, Karachi, Pakistan.
Methodology: This was a cross sectional observational study conducted using convenient sampling technique for seven months, from September 2017 till March 2018 in Oncology ward of Jinnah Postgraduate Medical Centre, Karachi after taking ethical approval. A total of 100 patients, who were admitted in haematology oncology unit diagnosed with acute myeloid leukemia were included in the study. Informed consent was taken from the patients with complete concealment of the data. The demographic data including age, gender and ethnicity of the patients was documented. Complete blood picture and other laboratory investigations included LFT’s (Total bilirubin, SGPT, ALT, ALK PO4), uric acid, LDH. The signs and symptoms recorded were fever, bleeding gums, weight loss, hepatomegaly, splenomegaly and lymphadenopathy. Bone marrow biopsy was taken. Remission acquired of AML was recorded. Descriptive analysis was done using SPSS version 20.0
Results: Among the total of 100 AML patients selected for this study, 60 (60%) were male and 40 (40%) were females. Mean age of patients was 31.89 ± 13.79 years. 29 (29%) of patients presented with complains of bleeding gums, 24 (24%) patients experienced weight loss, 12 (12%) patients had hepatomegaly, 7 (7%) patients had splenomegaly, 8(8%) patients had lymphadenopathy, and 53 (53%) of patients had acquired remission while 47 (47%) of patients did not acquire remission. Mean days of follow up were 26.47 ± 32.67 days. Mean level of haemoglobin was 9.94 ± 8.22 mg/dl. Mean level of total leukocyte count was 39.55 ± 57.78 mm3. Mean dose of Daunorubicin was 71.77 ± 8.84 mg and Cytarabine was 142.24 ± 21.71 mg.
Conclusion: The present study predicted that half of the patients acquired remission. A considerable number of patients with acute myelogenous leukemia, still fail toachieve complete remission (CR) with initial remission induction treatment
Impact Factor
2022: 6.012
This work is licensed under a